Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822561 · ClinicalTrials.gov registry record · Phase 2
Eplerenone for Central Serous Chorioretinopathy
A Phase 2 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01822561 is a Phase 2 study that has completed, run by Tufts Medical Center. The registered enrollment target is 17 participants.
The verdict
NCT01822561, a Phase 2 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
* The goal of the study is to examine the short-term effects and safety of a systemic anti-aldosterone medication, eplerenone, in a small group of patients with central serous chorioretinopathy (CSCR). * There is currently no standard treatment or therapy for either acute or chronic CSCR, a potentially debilitating eye disease. * There is evidence in both animals and humans that high blood serum corticosteroid levels can cause or worsen CSCR or findings similar to CSCR in the choroid and retina * Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR * The investigators' aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for both acute and chronic CSCR. * The study consists of taking a standard dose of eplerenone, 50mg once daily, for 1 month * Over the course of the month, patients will be monitored for side effects, as well as visual and anatomical response to the medication
Interventions
- DRUG Eplerenone 50mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822561
The ClinicalTrials.gov registry entry for NCT01822561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eplerenone 50mg is the first listed.
NCT01822561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822561 about?
NCT01822561 is a clinical study titled "Eplerenone for Central Serous Chorioretinopathy". * The goal of the study is to examine the short-term effects and safety of a systemic anti-aldosterone medication, eplerenone, in a small group of patients with central serous chorioretinopathy (CSCR). * There is currently no standard treatment or therapy for either acute or chronic CSCR, a potentia...
What is the current status of trial NCT01822561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2013-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01822561?
The interventions under investigation include: Eplerenone 50mg (DRUG).
Who is sponsoring clinical trial NCT01822561?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.